Anlotinib Hydrochloride Versus Imatinib Mesylate in Locally Advanced, Unresectable or Metastatic Chordoma: a Multicentre, Open-label, Randomised Phase 2 Trial
Conditions: Effect of Drugs; Quality of Life; Chordoma; Advanced Cancer Intervention: Drug: Anlotinib Hydrochloride Sponsors: Peking University People's Hospital; Peking University Shougang Hospital; Peking University Third Hospital; 3Peking University First Hospital; Beijing Jishuitan Hospital; People's Liberation Army General Hospital (301); Beijing Cancer Hospital; Cancer In stitute and Hospital, Chinese Academy of Medical Sciences Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Academies | Cancer | Cancer & Oncology | China Health | Chordoma | Gleevec | Hospitals | Research